<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125655</url>
  </required_header>
  <id_info>
    <org_study_id>F120628003</org_study_id>
    <nct_id>NCT03125655</nct_id>
  </id_info>
  <brief_title>Regulation of Inflammatory Genes in Psoriasis</brief_title>
  <official_title>Regulation of Inflammatory Genes in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory&#xD;
      changes in the skin. An extensive cytokine network including generated by activated dendritic&#xD;
      cells and T cells mediates the formation of psoriatic lesions. These immune-response&#xD;
      parameters can be used as markers in the severity and management of the disease after further&#xD;
      in-depth studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2014</start_date>
  <completion_date type="Anticipated">April 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory genes</measure>
    <time_frame>1 day</time_frame>
    <description>TNF-alpha , IFN-alpha , IL-6, IL-8, IL-12 , IL-23, IL-4, IL-5 and IL-10</description>
  </primary_outcome>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Psoriasis</condition>
  <condition>Inflammation</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Inflammatory markers</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 19 and older will be recruited from the Dermatology clinics at UAB&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of psoriasis&#xD;
&#xD;
          -  Must be age 19 or older.&#xD;
&#xD;
          -  Must be Fitzpatrick skin type I, II, III, IV, V, VI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who do not have photosensitive disease and are not on photosensitizing&#xD;
             medications.&#xD;
&#xD;
          -  Subjects with a history of keloids (who are more likely to develop hypertrophic scars&#xD;
             following skin biopsy).&#xD;
&#xD;
          -  Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants.&#xD;
&#xD;
          -  Subjects who are pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Cantrell</last_name>
      <phone>205-502-9960</phone>
      <email>wcantrell@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Nabiha Yusuf</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

